MLND Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (28 birž. 2021 @ 07:00):

Millendo Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing novel treatments for orphan endocrine diseases in the United States...

Stats
Dzisiejszy wolumen	1.91M
Średni wolumen	140 975
Kapitalizacja rynkowa	11.15M
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.0940 (8.87%)

Insider Trading

Date	Person	Action	Amount	type
2020-06-22	Nuechterlein Carole	Buy	12 000	Stock Option (right to buy)
2020-06-22	Howe John P Md	Buy	12 000	Stock Option (right to buy)
2020-06-22	Gallagher Carol Giltner	Buy	12 000	Stock Option (right to buy)
2020-06-22	Nichol Geoffrey	Buy	12 000	Stock Option (right to buy)
2020-06-22	Hindman James M.	Buy	12 000	Stock Option (right to buy)

INSIDER POWER
0.00
Last 34 transactions
Buy: 816 539 \| Sell: 0

Wolumen Korelacja

Długi: -0.37 (neutral)

Krótki: 0.79 (moderate)

Signal:(35.927) Neutral

Millendo Therapeutics Inc Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Millendo Therapeutics Inc Korelacja - Waluta/Towar

0.64
( weak )

-0.17
( neutral )

0.00
( neutral )

0.44
( neutral )

-0.77
( moderate negative )

-0.61
( weak negative )

Millendo Therapeutics Inc Finanse

Annual	2020
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-28.95

FY	2020
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-28.95

FY	2019
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-48.75

FY	2018
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-263.70

Financial Reports:

No articles found.

Millendo Therapeutics Inc

Millendo Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing novel treatments for orphan endocrine diseases in the United States. Its lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia; and MLE-301, a neurokinin 3-receptor antagonist for the treatment of vasomotor symptoms in menopausal women. The company is headquartered in Ann Arbor, Michigan.